Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study
- 1 August 2007
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 293 (2), E620-E627
- https://doi.org/10.1152/ajpendo.00217.2007
Abstract
Evidence from rodent studies indicates that the β-cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effects of the amylin analog pramlintide on body weight, 24-h caloric intake, portion sizes, “fast food” intake, and perceived control of eating in 88 obese subjects. After a 2-day placebo lead-in, subjects self-administered pramlintide (180 μg) or placebo by subcutaneous injection 15 min before meals for 6 wk without concomitant lifestyle modifications. Compared with placebo, pramlintide treatment elicited significant mean reductions from baseline in body weight on day 44 (−2.1 ± 0.3 vs. +0.1 ± 0.4%, P < 0.001), 24-h caloric intake (−990 ± 94 vs. −243 ± 126 kcal on day 3, P < 0.0001; −680 ± 86 vs. −191 ± 161 kcal on day 43, P < 0.01), portion sizes, and caloric intake at a “fast food challenge” (−385 ± 61 vs. −109 ± 88 kcal on day 44, P < 0.05). Pramlintide treatment also improved perceived control of eating, as demonstrated by a 45% placebo-corrected reduction in binge eating scores ( P < 0.01). The results of this translational research study confirm in humans various preclinical effects of amylin agonism, demonstrating that pramlintide-mediated weight loss in obese subjects is accompanied by sustained reductions in 24-h food intake, portion sizes, fast food intake, and binge eating tendencies.Keywords
This publication has 31 references indexed in Scilit:
- Pancreatic signals controlling food intake; insulin, glucagon and amylinPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2006
- Gastrointestinal hormones regulating appetitePhilosophical Transactions Of The Royal Society B-Biological Sciences, 2006
- Amylinergic control of food intakePhysiology & Behavior, 2006
- Gut peptides and the regulation of appetiteObesity Reviews, 2006
- Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and rewardPhysiology & Behavior, 2005
- The Gut and Energy Balance: Visceral Allies in the Obesity WarsScience, 2005
- The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axisAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Pramlintide for the Treatment of Insulin-Requiring Diabetes MellitusDrugs, 2004
- The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned ratsInternational Journal of Obesity, 2001
- Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylinPeptides, 1992